Fiche publication
Date publication
avril 2023
Journal
Stem cells translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KERDJOUDJ Halima
,
Dr GINDRAUX Florelle
Tous les auteurs :
Hofmann N, Lafarge X, Antica M, Ferry N, Girandon L, Gramignoli R, Jurga M, Kerdjoudj H, Navakauskiene R, Schiavi J, Shablii V, Nicolás FJ, Gindraux F
Lien Pubmed
Résumé
Perinatal derivatives (PnD) are drawing growing interest among the scientific community as an unrestricted source of multipotent stem cells, secretome, and biological matrices. They are useful for the treatment of diseases that currently have limited or no effective therapeutic options, but they require the development of regenerative approaches. With this development, the question of regulation of donation, processing, and distribution has therefore become more important. Within the European Cooperation in Science and Technology (COST) community, we compiled a group of international experts on PnD technologies, who revised and compared existing EU national regulations. Notably, despite clear European directives, each EU Country has developed their own implementation and standard levels for cell- and tissue-based therapies. To enable extended applications of PnD treatments within the EU community and worldwide, harmonization is highly recommended. This paper aims to provide an overview of the various options available to introduce PnD into clinical practice. For this purpose, the different aspects resulting from (1) the type of PnD, (2) the amount of available data, (3) the degree of manipulation, and (4) the intended application and the process toward a possible commercialization will be presented. In the future, it will be important to find a balance between regulatory requirements and the best medical quality of the PnD product.
Mots clés
ATMP, European regulation, cell therapy, perinatal tissues, placenta
Référence
Stem Cells Transl Med. 2023 04 7;:
